Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Phase 2/3 Recruiting
596 enrolled
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Phase 3 Recruiting
1,210 enrolled
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Phase 3 Recruiting
304 enrolled
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Phase 2/3 Recruiting
1,260 enrolled
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
660 enrolled
CheckMate-1533
Phase 2 Recruiting
76 enrolled
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Phase 2/3 Recruiting
854 enrolled
Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%
Phase 2 Recruiting
156 enrolled
A Study of ASP3082 in Adults With Advanced Solid Tumors
Phase 1 Recruiting
681 enrolled
INTerpath-009
Phase 3 Recruiting
680 enrolled
DL03
Phase 1 Recruiting
304 enrolled
Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
Phase 2 Recruiting
42 enrolled
PALOMA-2
Phase 2 Recruiting
520 enrolled
TroFuse-019
Phase 3 Recruiting
780 enrolled
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
Phase 1 Recruiting
500 enrolled
eVOLVE-01
Phase 2 Recruiting
180 enrolled
TroFuse-020
Phase 3 Recruiting
686 enrolled
Krascendo 2
Phase 3 Recruiting
600 enrolled
KANDLELIT-007
Phase 3 Recruiting
675 enrolled
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Phase 2 Recruiting
130 enrolled
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Phase 3 Recruiting
1,100 enrolled
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Phase 3 Recruiting
630 enrolled
MountainTAP-29
Phase 2/3 Recruiting
590 enrolled
REZILIENT4
Phase 3 Recruiting
360 enrolled
A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer
Phase 3 Recruiting
398 enrolled
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Phase 3 Recruiting
474 enrolled
IMMUNOLIFE2
Phase 2 Recruiting
162 enrolled
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Phase 1/2 Recruiting
295 enrolled
Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors
Phase 1/2 Recruiting
434 enrolled
eVOLVE-Meso
Phase 3 Recruiting
825 enrolled
MK-2870-009
Phase 3 Recruiting
520 enrolled
Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
Phase 2 Recruiting
318 enrolled
Pan Tumor Rollover Study
Phase 2 Recruiting
1,500 enrolled
SOHO-02
Phase 3 Recruiting
444 enrolled
RELATIVITY1093
Phase 3 Recruiting
1,000 enrolled
MK-3475-01E
Phase 2 Recruiting
60 enrolled
KRAS-Targeted Vaccine With Chemoimmunotherapy, Nivolumab and Ipilimumab for Patients With NSCLC
Phase 1 Recruiting
12 enrolled
ALTAIR
Phase 1/2 Recruiting
152 enrolled
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Phase 1/2 Recruiting
370 enrolled
Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
Recruiting
538 enrolled
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
340 enrolled
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
Phase 3 Recruiting
878 enrolled
SUNRAY-01
Phase 3 Recruiting
1,264 enrolled
Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC
Phase 2 Recruiting
23 enrolled
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Phase 1 Recruiting
387 enrolled
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
Phase 2 Recruiting
105 enrolled
KRAScendo 170
Phase 1/2 Recruiting
320 enrolled
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Phase 1 Recruiting
321 enrolled
SYNERGY-101
Phase 1/2 Recruiting
364 enrolled
VELOCITY-Lung
Phase 2 Recruiting
270 enrolled